Reports and Data, a market research firm, has released a report analyzing the global Mycoplasma Testing Market. In 2019, the market was valued at $609.39 million and is expected to reach $1.59 billion by 2027, growing at a CAGR of 12.6%.

Mycoplasma is the smallest bacteria discovered, having evolved from Gram-positive bacteria. They lack a cell wall and can be parasitic or saprotrophic. Though there are around 200 types of mycoplasma bacteria, most of them are harmless. Only five cause severe infections in humans, including Mycoplasma pneumonia, Mycoplasma genitalium, Mycoplasma hominis, Ureaplasma urealyticum, and Ureaplasma parvum, with different species causing different diseases. Testing for mycoplasma helps diagnose past or current infections in patients.

Get a free sample PDF of the report, visit @

https://www.reportsanddata.com/download-free-sample/2129

Mycoplasma microbes can exist as healthy flora in a patient’s throat, genitourinary tract, or respiratory tract, and because they lack a cell wall, they are immune to many antibiotics.

The mycoplasma testing market is driven by significant research and development activities in academia as well as the bio-pharmaceutical industry, increasing incidences of mycoplasma infections, and cell culture contamination. Mycoplasma can quickly spread through droplets during cell culture and are difficult to detect under a microscope; hence, specific tests are required for detection.

Furthermore, mycoplasma testing plays a critical role in cell culture, and testing must be performed at every stage of product development, including cell banks, viral seed stocks, and final products. The healthcare sector's growing expenditure by key market players to enhance customer satisfaction and achieve technological advancements is also expected to propel the global market for mycoplasma testing.

To know more about the latest insights of the report, visit @

https://www.reportsanddata.com/request-latest-insight/2129

The mycoplasma testing market is also driven by the increased adoption of mycoplasma testing in the microbiology sector, rising occurrences of mycoplasma infections, favorable investment scenarios for the healthcare industry through the public and private sectors, and growing awareness about mycoplasma bacterial infections. However, the lack of awareness of mycoplasma infections among patients and clinicians and the challenges related to detection are expected to hinder the market's growth.

The report found that the mycoplasma testing market is growing at a CAGR of 13.0% in Asia Pacific, followed by North America and Europe, with 12.8 % and 12.5% CAGR, respectively. Increasing government support, coupled with high investments in R&D, is a major factor driving market growth. Kits and reagents are the dominating Mycoplasma testing, holding 47.5% of the global market. The Asia Pacific regional market is the chief revenue-generating source for this product segment, followed by North America and Europe.

Mycoplasma contamination is a common but serious problem faced when culturing cells. Proper mycoplasma testing should be carried out before producing the final product to avoid this issue. For example, the MycoProbe Mycoplasma Detection Kit can be used for high-throughput and routine screening of cell culture for detecting mycoplasma contamination.

Key participants in the mycoplasma testing market include Thermo Fisher Scientific Inc. (U.S.), Lonza Group Ltd. (Switzerland), Merck KGaA (Germany), Roche Diagnostics (Switzerland), American Type Culture Collection (U.S.), Bionique Testing Laboratories, Inc. (U.S.), InvivoGen (U.S.), PromoCell GmbH (Germany), Norgen Biotek Corp. (Canada), GenBio (Canada), Meridian Bioscience, Inc. (U.S.), and Savyon Di.

Request customization of the report @

https://www.reportsanddata.com/request-customization-form/2129

Thank you for reading our report. Please connect with us to know more about the report and its customization feature. Our team will ensure the report is well suited to meet your requirements.

About Reports and Data 

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact:

John W, Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
LinkedIn | Twitter | Blogs